{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:37:01Z","timestamp":1787071021727,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In this study, we aimed to put forth the factors that contribute to the recurrence of mucinous ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Forty-four mucinous ovarian cancer patients who have presented to our clinic between February 2006 and May 2018 took part in the study. In order to predict the factors that contribute to recurrence, the univariate and the multivariate logistic regressions were utilized. The Kaplan\u2013Meier survival analysis was utilized for survival and the log-rank test was used for the discrepancies between the groups. In the analysis of the data, the Statistical Package for the Social Sciences 22 program was used. It was acknowledged to have statistical meaning when the P value in all the tests was lower than 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings:<\/jats:title>\n                    <jats:p>\n                      Recurrence was detected in 20 out of 44 patients who participated in the study. The ages of the patients who did not experience recurrence were significantly lower (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001). The patients were detected mostly in Stage 1 (36.4%). In the group of patients without recurrence, systemic lymphadenectomy (43.2%) was greater (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.019). Lymph node metastasis was three times higher in the group that experienced recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047). When the two groups were compared, the platinum resistance was considerably greater in the group with recurrence (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.005). In terms of residual tumor, the rate of complete resection was (9%) better in the group that experienced recurrence compared to the group that did not experience recurrence, with a rate of 45.5%. While 12 patients who experienced recurrence died, 6 people died in the other group. From the factors that contribute to recurrence, in terms of residual tumor quantity, this was grouped as complete (R0) resection and optimal + suboptimal (R1 + R2) resection and the following were determined: odds ratio (OR) \u2013 5.7 (95% confidence interval [CI]: 1.56\u201320.9) and\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008 for R1 + R2. In univariate analysis, the OR was determined as 1.16 (95% CI: 1.06\u20131.27) for age. Possessing a Stage 2 and higher disease statistically contributed considerably to the recurrence compared to Stage 1 disease (OR: 6.33; 95% CI: 1.59\u201325.22;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009). Age was determined as an independent prognostic risk factor in the multivariate analysis (OR: 1.10 [95% CI: 1.04\u20131.25]),\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018. Furthermore, the OR for the advanced-stage (Stage 2 or higher) patients in the multivariate analysis was determined as 7.88 (95% CI: 0.78\u201378.8) and was found to be statistically significant at limits (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.079).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We have put forth that the genetic, biological, and clinical characteristics of mucinous ovarian cancers differ from that of other epithelial ovarian cancers, and that age, advanced stage, and residual tumor quantity are prognostic risk factors in terms of recurrence, and that age is an independent prognostic risk factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Biological and clinical characteristics of mucinous ovarian cancers differ from those of other epithelial ovarian cancers, and we observed that the age, advanced stage, and the amount of residual tumor regarding recurrence are prognostic risk factors, while age was determined as an independent prognostic risk factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_109_21","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T10:51:34Z","timestamp":1689763894000},"page":"610-616","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Factors that contribute to the recurrence of mucinous ovarian cancer: Monocenter retrospective evaluation"],"prefix":"10.4103","volume":"19","author":[{"given":"\u00d6zer","family":"Birge","sequence":"first","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sait","family":"Bak\u0131r","sequence":"additional","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceyda","family":"Karadag","sequence":"additional","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selen","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan Aykut","family":"Tuncer","sequence":"additional","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayup","family":"Simsek","sequence":"additional","affiliation":[{"name":"Department of Gynecology Obstetrics, Division of Gynecologic Oncology, Akdeniz University, Antalya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,21]]},"reference":[{"key":"R1-20241021","first-page":"4","article-title":"Mucinous tumors of the ovary:A review","volume":"24","author":"Hart","year":"2005","journal-title":"Int J Gynecol Pathol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/01.PGP.0000070844.85581.A1","article-title":"History of gynecological pathology:XIV. Hermann Johannes Pfannenstiel","volume":"22","author":"Pickel","year":"2003","journal-title":"Int J Gynecol Pathol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00000478-200307000-00014","article-title":"Primary and metastatic mucinous adenocarcinomas in the ovaries:Incidence in routine practice with a new approach to improve intraoperative diagnosis","volume":"27","author":"Seidman","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R4-20241021","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jclinpath-2012-200843","article-title":"Pathology and prognosis in pseudomyxoma peritonei:A review of 274 cases","volume":"65","author":"Carr","year":"2012","journal-title":"J Clin Pathol"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PGP.0b013e31823f844d","article-title":"Metastatic mucinous carcinomas in the ovary:A practical approach to diagnosis related to gross aspects and to immunohistochemical evaluation","volume":"31","author":"Pinto","year":"2012","journal-title":"Int J Gynecol Pathol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer:A separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N Engl J Med"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer:A Gynecologic Oncology Group Study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2004.12.056","article-title":"Advanced stage mucinous epithelial ovarian cancer:The Hellenic Cooperative Oncology Group experience","volume":"97","author":"Pectasides","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R10-20241021","first-page":"3501","article-title":"Activity of chemotherapy in mucinous epithelial ovarian cancer:A retrospective study","volume":"25","author":"Pisano","year":"2005","journal-title":"Anticancer Res"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics,","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/00000478-200011000-00001","article-title":"Mucinous tumors of the ovary:A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'","volume":"24","author":"Lee","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ejca.2012.12.004","article-title":"Primary invasive mucinous ovarian carcinoma of the intestinal type:Importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases","volume":"49","author":"Muyldermans","year":"2013","journal-title":"Eur J Cancer"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/IGC.0000000000001202","article-title":"Characteristics and prognosis of stage I ovarian mucinous tumors according to expansile or infiltrative type","volume":"28","author":"Gouy","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/PAS.0b013e3181451b93","article-title":"Anaplastic carcinoma in mucinous ovarian tumors:A clinicopathologic study of 34 cases emphasizing the crucial impact of stage on prognosis, their histologic spectrum, and overlap with sarcomalike mural nodules","volume":"32","author":"Provenza","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal:A Gynecologic Oncology Group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/sj.bjc.6603003","article-title":"Adistinct molecular profile associated with mucinous epithelial ovarian cancer","volume":"94","author":"Heinzelmann-Schwarz","year":"2006","journal-title":"Br J Cancer"},{"key":"R20-20241021","first-page":"e3","article-title":"Mucinous ovarian carcinoma. Reply","volume":"381","author":"Morice","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum:Abridged republication","volume":"26","author":"Prat","year":"2015","journal-title":"J Gynecol Oncol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ygyno.2018.07.013","article-title":"Does the primary site really matter?Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials","volume":"150","author":"Meagher","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer:A review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol Med"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer:The ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"15 Suppl","key":"R28-20241021","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1200\/jco.2015.33.15_suppl.5528","article-title":"Multicentre trial of carboplatin\/paclitaxel versus oxaliplatin\/capecitabine, each with\/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC)","volume":"33","author":"Gore","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/00000478-200011000-00001","article-title":"Mucinous tumors of the ovary:A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei.'","volume":"24","author":"Lee","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2019.05.009","article-title":"Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma","volume":"154","author":"Nasioudis","year":"2019","journal-title":"Gynecol Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_109_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:27Z","timestamp":1787067627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_109_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_109_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"2021-01-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}